News

Candel Therapeutics Expands Research Board with Bali Pulendran

Candel Therapeutics Expands Research Board with Bali Pulendran

Appointment of Bali Pulendran to Research Advisory Board

Candel Therapeutics, Inc. (NASDAQ: CADL), a biopharmaceutical company dedicated to creating innovative cancer therapies, is thrilled to announce that it has appointed Bali Pulendran, Ph.D., an esteemed expert in systems immunology, to its Research Advisory Board (RAB). This strategic move aims to bolster the company's efforts in advancing its cutting-edge viral immunotherapy treatments designed to combat various forms of cancer.

Dr. Pulendran's Expertise and Vision

Dr. Bali Pulendran brings a wealth of knowledge to the Research Advisory Board, having established himself as a leader in the fields of systems immunology and vaccinology. He expressed his enthusiasm for joining Candel's team, noting, "I'm honored to join Candel's Research Advisory Board during this pivotal stage for the Company. Candel's innovative viral immunotherapy platform represents a compelling approach to activating the immune system against cancer." His extensive background will undoubtedly contribute significantly to the development of promising therapies that have the potential to transform cancer treatment.

Role and Contributions to Candel

As the Violetta L. Horton Professor at Stanford University School of Medicine and Director of the Institute for Immunity, Transplantation, and Infection, Dr. Pulendran has had a transformative impact on human immunology. His lineage of groundbreaking research includes the understanding of dendritic cells and their role in modulating immune responses, insights that will be invaluable as Candel continues to refine its product pipeline, including CAN-2409 and CAN-3110.

Candel's Innovative Viral Immunotherapy

The company is pioneering viral immunotherapy vaccines aimed at eliciting robust immune responses tailored to individual patients. CAN-2409 is a frontrunner from the adenovirus platform, currently undergoing advancement for various solid tumors. Recent clinical trials of CAN-2409, particularly in treating non-small cell lung cancer and pancreatic cancer, have shown encouraging results, and the FDA has granted it Fast Track Designation for specific treatment scenarios.

Commitment to Clinical Innovation

Additionally, CAN-3110, the lead product candidate from the herpes simplex virus platform, is in phase 1b trials for high-grade glioma, showcasing Candel's commitment to addressing urgent medical needs in oncology. The company's enLIGHTEN™ Discovery Platform leverages advanced analytics to innovate new treatments that harness the body's immune system effectively against tumors.

Future Directions and Patient Impact

Candel Therapeutics boasts a firm commitment to developing therapies that expand treatment options and improve patient outcomes in cancer care. With Dr. Pulendran's appointment, there is great optimism about the potential acceleration of research initiatives and therapeutic advancements. As Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO of the company, remarked, "His insights into immune responses will provide invaluable perspectives as we strive toward breakthroughs in cancer treatment, addressing critical needs for patients."

About Candel Therapeutics

Candel Therapeutics is at the forefront of cancer therapy innovation, focusing on fully integrated viral immunotherapies designed to provoke strong systemic responses against tumors. Their proficiency in developing unique biopharmaceutical platforms aims to transform the landscape of cancer treatment. To keep up with the latest from Candel, potential investors and interested parties are encouraged to visit their official website.

Frequently Asked Questions

1. What is Candel Therapeutics known for?

Candel Therapeutics is a clinical-stage biopharmaceutical company specializing in developing viral immunotherapies for cancer treatment.

2. Who has been appointed to the Research Advisory Board?

Bali Pulendran, Ph.D., an expert in systems immunology, has recently joined the Research Advisory Board at Candel Therapeutics.

3. What are the primary therapies being developed by Candel?

Candel is developing CAN-2409 and CAN-3110, targeting various solid tumors and recurrent high-grade glioma respectively.

4. How has the FDA recognized Candel's products?

The FDA has granted Fast Track Designation and Orphan Drug Designation to Candel’s therapies, indicating their potential significance in treating critical conditions.

5. How can I get more information about Candel Therapeutics?

For more detailed information about Candel Therapeutics and their innovative therapies, you can visit their website at www.candeltx.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

UBCF & GGP Join Forces for Nationwide Pink Bag Drive

Updated Category News Views 245

Caring Through Community: Pink Bag Events Unroll What do you get when compassion meets action? That's the story with the United Breast Cancer Foundation (UBCF) and GGP's Pink Bag Event. Here in 2026, these folks are doing something so damn important, you'd wonder why more don’t follow suit. For the fifth straight year, they're rolling out a campaign that bridges the gap...

Continue Reading
Langford Chosen for Navy Mutual's 2026 Bolles Award

Updated Category News Views 389

Awarding a Military Financial Educator There's something profoundly rewarding when hard work and dedication get their due recognition. That's precisely what's happened for Lacey Langford, who’s just been awarded the Lieutenant Timothy Dix Bolles Excellency in Education Award by the Navy Mutual Aid Association, or simply Navy Mutual. This isn’t just some...

Continue Reading
Rural AI Skills Gap Uncovered: Challenges and Solutions

Updated Category News Views 179

Rural Workers Face Distinct AI Challenges Ah, life in the countryside might sound serene, but when it comes to keeping up with AI, rural folks aren't sipping lemonade and waiting on a windfall. The newly unveiled paper from the University of Phoenix College of Doctoral Studies shines a floodlight on some hefty challenges facing rural communities—particularly around...

Continue Reading
Bass Angler Matt Robertson Reels in Record $1.25M Prize

Updated Category News Views 195

A New Era for Bass Fishing Payouts Who would have thought we'd see the day when bass fishing turned out to be as lucrative as a Wall Street handshake? But here we are, with Matt Robertson hauling in a whopping $1.25 million prize at World Bass Enterprises' first "The Champions" Tournament. We're not talking chump change here—this is the real deal in a sport often...

Continue Reading
Yangtze River Culture Festival Spotlights Integration, Tradition

Updated Category News Views 213

A Celebration of Culture and Integration Here's an event that flips the script on the typical festival circuit: the 2026 Yangtze River Culture Festival. It's as much about heritage as it is about economics, dovetailing culture with tourism in a way that makes wallets a little fatter and souls a little richer. Kicking off in Yonglian Village, Zhangjiagang, this festival...

Continue Reading
Race for Life Rescue Logs 200 Flights for Shelter Pets

Updated Category News Views 318

Airborne Lifelines for Vulnerable Animals Ever picture an airplane filled with hope? Well, Race for Life Rescue isn't just carting metal through the sky; they're lifting spirits, one furry passenger at a time. Picture this: a nonprofit turning a clunky Beechcraft into a flying ark, whisking away 112 at-risk pets from Louisiana to fresh starts in the Northeast. And guess...

Continue Reading
Can AI Help Climate? Tech Investments Seek Balance

Updated Category News Views 191

Is AI a Climate Savior or a Power-Hungry Beast? AI might feel like that unpredictable family member you hope shows up to the party with something useful, but they’ve always got high energy bills. As the tech world touts artificial intelligence as the next big hope for addressing climate woes, folks like Peter Gilmer—who's been around a few boardrooms—are taking a...

Continue Reading
Naviu's AI Travel Guide: Revolutionizing Japan Tours

Updated Category News Views 168

A New Era of Touring Japan: Meet Naviu Alright, travelers, strap in—Naviu is about to flip your trip to Japan upside down. Launching November 1st, 2026, this AI-powered augmented reality travel companion is trying to make exploring Japan easier than ever. Behind this innovative gem is TANGLE Inc., working with technology so cutting-edge, it's practically slicing through...

Continue Reading
Wulcea Pioneers Safety in Smart Heated Apparel

Updated Category News Views 164

Tech Behind the Warmth and Safety You ever turn on a heated jacket and wonder if it'll keep you safe as much as warm? That's the scene with Wulcea, a brand diving headfirst into the smart heated clothing market. People are waking up to what’s inside these technological coats, not just how they feel on a frosty walk. It’s the kind of scenario where safety meets...

Continue Reading
ModelBest & OpenBMB Unveil Open-Source OCR Models

Updated Category News Views 189

A New Frontier in Document Parsing Just when you thought document parsing couldn't get any more advanced, ModelBest and OpenBMB come along with a game-changing release: the MiniCPM-OCR series. This duo of dynamite models, MiniCPM-OCR 1.0 and Jev, is all about taking the efficiency and performance expectations for open-source OCR models up a couple of notches. If you're an...

Continue Reading

Top 5 Most Recently Viewed Articles

Progyny Expands Women's Health Services with New Therapy Offerings

Updated Category News Views 160

Progyny Expands Women's Health Services with New Therapy Offerings Progyny, Inc. (Nasdaq: PGNY), a prominent leader in women's health and family building solutions, has announced a significant expansion of its services by adding pelvic floor therapy to its diverse array of offerings. This latest initiative underscores the company's commitment to enhancing healthcare...

Continue Reading
Innovative Strategies Transforming Ambulatory Care with AI

Updated Category News Views 240

Revolutionizing Ambulatory Care with Innovative Technologies Greenway Health, a leader in health information technology, is set to change the landscape of ambulatory care with its groundbreaking introduction: The Automated Healthcare Practice. This innovative platform, unveiled at a major customer event, signifies a substantial transformation in the way healthcare is...

Continue Reading
Earnings Preview: Community Healthcare Faces Market Scrutiny

Updated Category News Views 165

Community Healthcare (NYSE:CHCT) is set to unveil its quarterly earnings on February 17, and the buzz is already electric. Analysts are projecting an earnings per share (EPS) of $0.47, a figure that's dancing right on the edge of what investors want to see. Now, here’s where it gets juicy: last time around, CHCT outperformed EPS expectations by a solid $0.33—but hold...

Continue Reading
Alphabet's Short Interest: What Traders Need to Know

Updated Category News Views 241

Alphabet Inc's (NYSE:GOOGL) recent short interest report is making waves—short interest as a percent of float dropped by 9.03%. That leaves us with 75.95 million shares sold short, which amounts to about 1.31% of all regular trading shares available. And here's the kicker: based on current trading volume, it would take traders an average of 2.48 days to cover their...

Continue Reading
Understanding AppLovin Inc's Price-to-Earnings Dynamics

Updated Category News Views 79

Analyzing AppLovin Inc's Stock Performance As the market evolves, investors keep a close eye on stock prices. Currently, AppLovin Inc. (NASDAQ: APP) is trading at $683.87, reflecting a slight increase of 1.97%. This upward trend has caught the attention of both short-term traders and long-term shareholders. Over the past month, the stock achieved a remarkable increase of...

Continue Reading